Clarivate Plc (FRA:16A)
| Market Cap | 1.96B |
| Revenue (ttm) | 2.13B |
| Net Income (ttm) | -337.51M |
| Shares Out | n/a |
| EPS (ttm) | -0.49 |
| PE Ratio | n/a |
| Forward PE | 5.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 666 |
| Average Volume | 33 |
| Open | 3.000 |
| Previous Close | 2.700 |
| Day's Range | 2.720 - 3.000 |
| 52-Week Range | 2.400 - 5.300 |
| Beta | n/a |
| RSI | 47.44 |
| Earnings Date | Feb 19, 2026 |
About Clarivate
Clarivate Plc operates as an information services provider in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. It operates through three segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. The company provides scientific and academic research, a connect data, solutions, and expertise so that research institutions can thrive; ProQuest One solutions provide access to multidisciplinary curated content across a variety of formats including data bases, dissertations, news, primary sources, book... [Read more]
Financial Performance
In 2024, Clarivate's revenue was $2.56 billion, a decrease of -2.74% compared to the previous year's $2.63 billion. Losses were -$668.00 million, -32.29% less than in 2023.
Financial numbers in USD Financial StatementsNews
Goldman Sachs Downgrades Clarivate (CLVT) with Lower Price Target | CLVT Stock News
Goldman Sachs Downgrades Clarivate (CLVT) with Lower Price Target | CLVT Stock News
Wall Street Breakfast Podcast: DHS Calls Out Hilton Over ICE
Hilton faces DHS ire after ICE agents were denied rooms at Minneapolis hotel. Hawaiian Electric reaches $47.75M shareholder settlement over wildfires. Clarivate unveils 2026 Drugs to Watch.
Clarivate (CLVT) Highlights Key Therapies in 2026 Drugs to Watch Report
Clarivate (CLVT) Highlights Key Therapies in 2026 Drugs to Watch Report
Clarivate Plc: Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient careLONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a ...
Clarivate unveils 2026 Drugs to Watch highlighting 11 promising therapies
Clarivate’s 2026 Drugs to Watch report spotlights 11 high-potential therapies across cancer, metabolic, immune & rare diseases—see what trends to watch now.
Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient care LONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a lea...
Clarivate Plc: Nissan Selects IPfolio from Clarivate
Managing IP with advanced workflow automation technology and leading dataLONDON, Dec. 18, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence,...
Nissan Selects IPfolio from Clarivate
Managing IP with advanced workflow automation technology and leading data LONDON , Dec. 18, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, a...
CLVT Downgraded by Morgan Stanley with a Lowered Price Target | CLVT Stock News
CLVT Downgraded by Morgan Stanley with a Lowered Price Target | CLVT Stock News
Clarivate (CLVT) Unveils AI-Powered Regulatory Intelligence Tool
Clarivate (CLVT) Unveils AI-Powered Regulatory Intelligence Tool
Clarivate Plc: Clarivate Presents Cortellis Regulatory AI Assistant to Cut Through Complexity in Safety and Compliance
Powered by agentic AI, new features help regulatory teams improve accuracy and enable faster, more confident decisions across the product lifecycleLONDON, Dec. 4, 2025 /PRNewswire/ -- Clarivate Pl...
Clarivate Presents Cortellis Regulatory AI Assistant to Cut Through Complexity in Safety and Compliance
Powered by agentic AI, new features help regulatory teams improve accuracy and enable faster, more confident decisions across the product lifecycle LONDON , Dec. 4, 2025 /PRNewswire/ -- Clarivate Plc ...
Insider Sell: Bar Veinstein Sells 309,902 Shares of Clarivate PLC (CLVT)
Insider Sell: Bar Veinstein Sells 309,902 Shares of Clarivate PLC (CLVT)
Clarivate Launches Derwent Patent Monitor to Enable Fast and Accurate Decision-making with AI
New enterprise solution streamlines IP and R&D patent reviews and accelerates freedom to operate, patentability, and infringement related decisions LONDON , Nov. 24, 2025 /PRNewswire/ -- Clarivate Plc...
Clarivate Plc (CLVT) Presents at Global Technology, Internet, Media & Telecommunications Conference 2025 Transcript
Clarivate Plc (CLVT) Global Technology, Internet, Media & Telecommunications Conference 2025 November 19, 2025 1:20 PM ESTCompany ParticipantsMatti Shem...
Clarivate to Present at the RBC Capital Markets Global Technology, Internet, Media and Telecommunications Conference on November 19
LONDON , Nov. 13, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Matt Shem Tov, Chief Executive Officer, and Jonathan C...
Clarivate Announces Highly Cited Researchers 2025 List
Celebrating exceptional, community-wide excellence, based on rigorous evaluation and selection LONDON , Nov. 12, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transforma...
Is Clarivate Stock a Buy After a Member of the Board of Directors Bought Shares for $2.5 Million?
Key PointsKenneth L. Cornick, a member of the Board of Directors for Clarivate, purchased 725,000 shares in the company.
Is Clarivate Stock a Buy After a Member of the Board of Directors Bought Shares for $2.5 Million?
Kenneth L. Cornick, a member of the Board of Directors for Clarivate, purchased 725,000 shares in the company. The purchase came a few days after Clarivate reported third quarter results on Oct. 29.
Fujifilm Selects IPfolio from Clarivate
Maximizing the value of intellectual property assets to support business growth LONDON , Nov. 6, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligen...
Clarivate: Downgrade To Hold As The Recovery Momentum Is Not Showing Up
Clarivate faces weak organic growth and flat revenue with challenges in key segments and slow recovery. Learn why CLVT stock is downgraded to hold.
Clarivate PLC (CLVT) Q3 2025 Earnings Call Highlights: Strategic Innovations and Financial ...
Clarivate PLC (CLVT) Q3 2025 Earnings Call Highlights: Strategic Innovations and Financial Resilience Amidst Challenges
Q3 2025 Clarivate PLC Earnings Call Transcript
Q3 2025 Clarivate PLC Earnings Call Transcript
Clarivate Pulse of the Library Report Reveals Link Between AI Literacy, AI Implementation and Confidence
D rawing on insights from over 2,000 librarians representing academic, national and public libraries globally, the report offers an up-to-date view of how they are adapting to rapid change LONDON , Oc...
Decoding Clarivate PLC (CLVT): A Strategic SWOT Insight
Decoding Clarivate PLC (CLVT): A Strategic SWOT Insight